Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
17.50
-0.20 (-1.13%)
At close: Aug 29, 2025, 4:00 PM
17.49
-0.01 (-0.06%)
After-hours: Aug 29, 2025, 6:21 PM EDT
Travere Therapeutics Employees
Travere Therapeutics had 385 employees as of December 31, 2024. The number of employees increased by 5 or 1.32% compared to the previous year.
Employees
385
Change (1Y)
5
Growth (1Y)
1.32%
Revenue / Employee
$867,182
Profits / Employee
-$439,106
Market Cap
1.56B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 385 | 5 | 1.32% |
Dec 31, 2023 | 380 | -82 | -17.75% |
Dec 31, 2022 | 462 | 152 | 49.03% |
Dec 31, 2021 | 310 | 48 | 18.32% |
Dec 31, 2020 | 262 | 41 | 18.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TVTX News
- 3 days ago - FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari - Benzinga
- 4 days ago - Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy - Business Wire
- 19 days ago - Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore - Seeking Alpha
- 20 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Travere Therapeutics Reports Second Quarter 2025 Financial Results - Business Wire
- 26 days ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Travere Therapeutics to Report Second Quarter 2025 Financial Results - Business Wire